Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanna I Hyry

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Eye (London, England)|December 1, 2018
Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for bothHanna I Hyry, Jonathan C P Roos
The New England Journal of Medicine|May 14, 2020
Teprotumumab for Active Thyroid Eye DiseaseJonathan C P Roos, Hanna I Hyry, Rachna Murthy
Expert Review of Pharmacoeconomics & Outcomes Research|January 16, 2016
Saving orphan drug legislations: misconceptions and clarificationsHanna I Hyry, Timothy M Cox, Jonathan C P Roos
Current Medical Research and Opinion|January 20, 2017
Brexit and rare diseases: big risk, bigger opportunity?Hanna I Hyry, Timothy M Cox, Jonathan C P Roos
BMJ (Clinical Research Ed.)|November 18, 2010
Orphan drug pricing may warrant a competition law investigationJonathan C P Roos, Hanna I Hyry, Timothy M Cox
Orphanet Journal of Rare Diseases|September 10, 2013
The legal imperative for treating rare disordersHanna I Hyry, Jonathan C P Roos, Jeremy Manuel, et al.
Orphanet Journal of Rare Diseases|August 22, 2015
Compassionate use of orphan drugsHanna I Hyry, Jeremy Manuel, Timothy M Cox, et al.
Molecular Genetics and Metabolism|August 21, 2017
Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and managementJonathan C P Roos, Matthew J Daniels, Elizabeth Morris, et al.
Lancet (London, England)|July 25, 2018
Outrageous prices of orphan drugs: a call for collaborationLucio Luzzatto, Hanna I Hyry, Arrigo Schieppati, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Eye (London, England)|December 1, 2018
Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for bothHanna I Hyry, Jonathan C P Roos
The New England Journal of Medicine|May 14, 2020
Teprotumumab for Active Thyroid Eye DiseaseJonathan C P Roos, Hanna I Hyry, Rachna Murthy
Expert Review of Pharmacoeconomics & Outcomes Research|January 16, 2016
Saving orphan drug legislations: misconceptions and clarificationsHanna I Hyry, Timothy M Cox, Jonathan C P Roos
Current Medical Research and Opinion|January 20, 2017
Brexit and rare diseases: big risk, bigger opportunity?Hanna I Hyry, Timothy M Cox, Jonathan C P Roos
BMJ (Clinical Research Ed.)|November 18, 2010
Orphan drug pricing may warrant a competition law investigationJonathan C P Roos, Hanna I Hyry, Timothy M Cox
Orphanet Journal of Rare Diseases|September 10, 2013
The legal imperative for treating rare disordersHanna I Hyry, Jonathan C P Roos, Jeremy Manuel, et al.
Orphanet Journal of Rare Diseases|August 22, 2015
Compassionate use of orphan drugsHanna I Hyry, Jeremy Manuel, Timothy M Cox, et al.
Molecular Genetics and Metabolism|August 21, 2017
Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and managementJonathan C P Roos, Matthew J Daniels, Elizabeth Morris, et al.
Lancet (London, England)|July 25, 2018
Outrageous prices of orphan drugs: a call for collaborationLucio Luzzatto, Hanna I Hyry, Arrigo Schieppati, et al.
Pageof 1